The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).
Verkerk K, Zeverijn LJ, van de Haar J, Roepman P, Geurts BS, Spiekman AC, van der Noort V, van Berge Henegouwen JM, Hoes LR, van der Wijngaart H, Jansen AML, de Leng WWJ, Gelderblom AJ, Verheul HMW, Voest EE.
Verkerk K, et al. Among authors: jansen aml.
ESMO Open. 2025 Jan 7;10(1):104112. doi: 10.1016/j.esmoop.2024.104112. Online ahead of print.
ESMO Open. 2025.
PMID: 39778224
Free article.